MediWound wins $3.3 million US Department of War grant for room-temperature NexoBrid development
MDWD•North American rights remain with Vericel
The project falls under Vericel’s North American license, which grants Vericel exclusive development and commercial rights to NexoBrid in the region.
Additional grant supports room-temperature NexoBrid formulation
MediWound received an additional USD 3.3 million award from the US Department of War for a room-temperature-stable NexoBrid formulation.
Total program budget increased to USD 21.8 million, supporting development through an FDA IND submission for battlefield burn care.
